Cedirogant’s Dose-Proportional Pharmacokinetics and Safety Profile Support Advancement to Phase II Clinical Trial for Psoriasis Symptoms Improvement.

https://pubmed.ncbi.nlm.nih.gov/38112262

The sentence: “Cedirogant, an inverse agonist of RORγt, showed dose-proportional pharmacokinetics, good safety profile, and numerical improvement in psoriasis symptoms in a phase I study, supporting its advancement to phase II clinical trial.”